Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting

Kiyotaka Yoh, Yasushi Goto, Yoichi Naito, Kazuma Kishi, Kiyoshi Mori, Katsuyuki Hotta, Yukio Hosomi, Kazuhiko Yamada, Chiharu Tanai, Yoshio Tomizawa, Akira Inoue, Yoshinori Hasegawa, Makoto Nishio, Yasuo Ohashi, Hideo Kunitoh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a realworld setting. Patients and Methods: This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up. Results: Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy. Conclusion: Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.

Original languageEnglish
Pages (from-to)1507-1513
Number of pages7
JournalAnticancer Research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Maintenance
Drug Therapy
Platinum
Multicenter Studies
Cohort Studies
Observation
Survival
Population

Keywords

  • Maintenance therapy
  • Non-small cell lung cancer
  • Platinum-based chemotherapy
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting. / Yoh, Kiyotaka; Goto, Yasushi; Naito, Yoichi; Kishi, Kazuma; Mori, Kiyoshi; Hotta, Katsuyuki; Hosomi, Yukio; Yamada, Kazuhiko; Tanai, Chiharu; Tomizawa, Yoshio; Inoue, Akira; Hasegawa, Yoshinori; Nishio, Makoto; Ohashi, Yasuo; Kunitoh, Hideo.

In: Anticancer Research, Vol. 37, No. 3, 01.03.2017, p. 1507-1513.

Research output: Contribution to journalArticle

Yoh, K, Goto, Y, Naito, Y, Kishi, K, Mori, K, Hotta, K, Hosomi, Y, Yamada, K, Tanai, C, Tomizawa, Y, Inoue, A, Hasegawa, Y, Nishio, M, Ohashi, Y & Kunitoh, H 2017, 'Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting', Anticancer Research, vol. 37, no. 3, pp. 1507-1513. https://doi.org/10.21873/anticanres.11478
Yoh, Kiyotaka ; Goto, Yasushi ; Naito, Yoichi ; Kishi, Kazuma ; Mori, Kiyoshi ; Hotta, Katsuyuki ; Hosomi, Yukio ; Yamada, Kazuhiko ; Tanai, Chiharu ; Tomizawa, Yoshio ; Inoue, Akira ; Hasegawa, Yoshinori ; Nishio, Makoto ; Ohashi, Yasuo ; Kunitoh, Hideo. / Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting. In: Anticancer Research. 2017 ; Vol. 37, No. 3. pp. 1507-1513.
@article{cce40e562c1549fd9cca17d98d99d682,
title = "Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting",
abstract = "Background: The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a realworld setting. Patients and Methods: This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up. Results: Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29{\%}) did not receive second-line therapy. In contrast, only 18{\%} of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy. Conclusion: Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.",
keywords = "Maintenance therapy, Non-small cell lung cancer, Platinum-based chemotherapy, Second-line therapy",
author = "Kiyotaka Yoh and Yasushi Goto and Yoichi Naito and Kazuma Kishi and Kiyoshi Mori and Katsuyuki Hotta and Yukio Hosomi and Kazuhiko Yamada and Chiharu Tanai and Yoshio Tomizawa and Akira Inoue and Yoshinori Hasegawa and Makoto Nishio and Yasuo Ohashi and Hideo Kunitoh",
year = "2017",
month = "3",
day = "1",
doi = "10.21873/anticanres.11478",
language = "English",
volume = "37",
pages = "1507--1513",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting

AU - Yoh, Kiyotaka

AU - Goto, Yasushi

AU - Naito, Yoichi

AU - Kishi, Kazuma

AU - Mori, Kiyoshi

AU - Hotta, Katsuyuki

AU - Hosomi, Yukio

AU - Yamada, Kazuhiko

AU - Tanai, Chiharu

AU - Tomizawa, Yoshio

AU - Inoue, Akira

AU - Hasegawa, Yoshinori

AU - Nishio, Makoto

AU - Ohashi, Yasuo

AU - Kunitoh, Hideo

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a realworld setting. Patients and Methods: This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up. Results: Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy. Conclusion: Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.

AB - Background: The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a realworld setting. Patients and Methods: This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up. Results: Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy. Conclusion: Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy.

KW - Maintenance therapy

KW - Non-small cell lung cancer

KW - Platinum-based chemotherapy

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=85015843801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015843801&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11478

DO - 10.21873/anticanres.11478

M3 - Article

VL - 37

SP - 1507

EP - 1513

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -